On June 17, Abivax S.A. rose 5.15% in regular trading, trading at $102.43/share, with turnover of approximately $58.39 million.

On the news front, the stock continues its technical rebound after earlier safety concerns surrounding the companys core drug obefazimod were largely digested by the market. The Phase 3 ABTECT maintenance trial had previously triggered a sell-off when multiple cancer cases emerged in the 50mg dosing group, sending shares plunging from approximately $130 to around $70 — a decline of nearly 50%. Some investors now believe the cancer cases are more likely correlated with patient age rather than the drug itself, suggesting the prior market reaction may have been excessive.

However, headwinds remain. Wedbush Securities has flagged elevated risk of a black box warning for the drug, and The Schall Law Firm has initiated a securities fraud investigation into whether the company issued false or misleading statements regarding clinical trial results. The current rebound reflects buyer momentum gaining the upper hand in the ongoing bull-bear contest from deeply oversold levels, though legal and regulatory overhangs persist.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)